ASH 2018 | Ipilimumab, nivolumab & brentuximab vedotin for R/R Hodgkin lymphoma

Stephen Ansell

Relapsed/refractory Hodgkin lymphoma (R/R HL) continues to pose a significant clinical challenge. Here, Stephen Ansell, MD, PhD, of the Mayo Clinic, Rochester, MI, presents the preliminary safety and response data from the Phase I/II E4412 trial (NCT01896999) investigating ipilimumab and nivolumab when given together with brentuximab vedotin for the treatment of R/R HL. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video